Showing 2961-2970 of 5257 results for "".
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- NeoStrata Launches Exuviance Triple Microdermabrasionhttps://practicaldermatology.com/news/20140530-neostrata_launches_exuviance_triple_microdermabrasion/2459226/NeoStrata Company's new Exuviance Triple Microdermabrasion, described as a three-part approach to skin renewal in one single treatment, will be available nationwide in August. Exuviance Triple Microdermabrasion is formulated with professional grade crystals and Papaya Enzymes along with 1
- New Data Demonstrate Significant Long-term Improvement in Scarring using Neodyne Biosciences embrace® Advanced Scar Therapyhttps://practicaldermatology.com/news/20140519-new_data_demonstrate_significant_long-term_improvement_in_scarring_using_neodyne_biosciences_embrace_advanced_scar_therapy/2459236/Neodyne Biosciences reported a highly significant improvement in scarring for patients treated with embrace® Advanced Scar Therapy versus control at
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical applicat
- Modernizing Medicine's EMA Achieves ONC HIT 2014 Edition EHR Certificationhttps://practicaldermatology.com/news/20140506-modernizing_medicines_ema_achieves_onc_hit_2014_edition_ehr_certification/2459245/Modernizing Medicine's EMA has achieved ONC HIT 2014 Edition Complete EHR certification, meaning that it will be capable of supporting eligible providers and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures of the EHR incentive program. EMA version 4.0 and EMA Mobile version 4.
- The XV World Congress on Cancers of the Skin to be Held in Edinburghhttps://practicaldermatology.com/news/20140501-the_xv_world_congress_on_cancers_of_the_skin_to_be_held_in_edinburgh/2459248/The XV World Congress on Cancers of the Skin, co-sponsored by The Skin Cancer Foundation and the British Association of Dermatologists, will be held at the Edinburgh International Conference Centre in Edinburgh, Scotland, September 3-6, 2014. The World Congress provides an opportunity for physic
- Outrun the Sun Marks 10 Years of Sun Safety Education and Melanoma Researchhttps://practicaldermatology.com/news/20140428-outrun_the_sun_marks_10_years_of_sun_safety_education_and_melanoma_research/2459253/Outrun the Sun, Inc. (OTS), a nonprofit organization that has raised more than $1 million in support of skin cancer education and melanoma research, celebrates their 10 year anniversary. OTS was formed by Anita Day, Jonna MacDougall, Marci Reddick and Jennifer Patton Sarno because they h
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is
- bioskin Continues US Expansion with Launch of New Websitehttps://practicaldermatology.com/news/20140417-bioskin_continues_us_expansion_with_launch_of_new_website/2459268/bioskin® follows expansion of its US office, spearheaded by AJ Acker, Executive Director of Global Regulatory and Clinical Affairs, with the launch of our a website www.bioskinCRO.com. The new layout was designed with ease of u